Mirum and Incyte gain approval of zilurgisertib for rare bone disorder

Jonathan Block

• The US FDA on Friday approved Mirum Pharmaceuticals (MIRM) and Incyte's (INCY) Atebrioz (zilurgisertib) as a treatment for the rare bone condition fibrodysplasia ossificans progressiva (FOP).
• The therapy is designed to reduce the volume of total new heterotopic ossification in adults

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.